{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:28:38Z","timestamp":1786120118238,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/wco.0b013e32834a9433","type":"journal-article","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T05:32:54Z","timestamp":1312608774000},"page":"463-468","source":"Crossref","is-referenced-by-count":31,"title":["Fabry disease"],"prefix":"10.1097","volume":"24","author":[{"given":"Keiko","family":"Toyooka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease.","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","article-title":"Physiological characterization of neuropathy in Fabrys disease.","volume":"26","author":"Luciano","year":"2002","journal-title":"Muscle Nerve"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","article-title":"Small fiber dysfunction predominates in Fabry neuropathy.","volume":"19","author":"Dutsch","year":"2002","journal-title":"J Clin Neurophysiol"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archneur.1974.00490380068009","article-title":"Loss of small peripheral sensory neurons in Fabry disease.","volume":"31","author":"Ohnishi","year":"1974","journal-title":"Arch Neurol"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s004150050125","article-title":"Nerve biopsy findings in hemizygous and heterozygous patients with Fabrys disease.","volume":"244","author":"Toyooka","year":"1997","journal-title":"J Neurol"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/WNL.52.6.1249","article-title":"Quantitative analysis of epidermal innervation in Fabry disease.","volume":"52","author":"Scott","year":"1999","journal-title":"Neurology"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","article-title":"Neuropathic symptoms and findings in women with Fabry disease.","volume":"119","author":"Laaksonen","year":"2008","journal-title":"Clin Neurophysiol"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","article-title":"Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.","volume":"145","author":"Moller","year":"2009","journal-title":"Pain"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1529-8027.2009.00227.x","article-title":"Autonomic skin responses in females with Fabry disease.","volume":"14","author":"Moller","year":"2009","journal-title":"J Peripheral Nerv Syst"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.21606","article-title":"Small fiber neuropathy in female patients with Fabry disease.","volume":"41","author":"Liguori","year":"2010","journal-title":"Muscle nerve"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/mus.21383","article-title":"Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease.","volume":"40","author":"Tavakoli","year":"2009","journal-title":"Muscle Nerve"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2010.03227.x","article-title":"Frequency of Fabry disease in patients with small-fibre neuropathy of unknown etiology: a pilot study.","volume":"18","author":"Tanislav","year":"2011","journal-title":"Eur J Neurol"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-1811(98)00032-2","article-title":"The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidorosis.","volume":"18","author":"Lao","year":"1998","journal-title":"J Dermatol Sci"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2377-10-38","article-title":"Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic System Profile and cardiovascular autonomic function tests.","volume":"10","author":"Biegstraaten","year":"2010","journal-title":"BMC Neurol"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabrys disease.","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1440-1789.2008.00883.x","article-title":"An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia.","volume":"28","author":"Okeda","year":"2008","journal-title":"Neuropathology"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease.","volume":"257","author":"Moore","year":"2007","journal-title":"J Neurol Sci"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","article-title":"The pulvinar sign: frequency and clinical correlation in Fabry disease.","volume":"255","author":"Burlina","year":"2008","journal-title":"J Neurol"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/01.wnl.0000338566.54190.8a","article-title":"Diagnostic utility of different MRI and MR angiography measures in Fabry disease.","volume":"72","author":"Fellgiebel","year":"2009","journal-title":"Neurology"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry.","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: The PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients.","volume":"41","author":"Baptista","year":"2010","journal-title":"Stroke"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease.","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from Fabry Registry.","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial.","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy: a retrospective analysis from the Fabry Outcome Survey.","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin J Pain"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabrys disease: an analysis of registry data.","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human (alpha)-galactosidase A replacement therapy in Fabrys disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, A-, and A-nerve fibers in Fabry neuropathy.","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drug"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease.","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Therapeut"},{"key":"R37-9-20210206","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions.","volume":"7","author":"Alfadhel","year":"2011","journal-title":"Ther Clin Risk Manage"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.","volume":"251","author":"Hilz","year":"2004","journal-title":"J Neurol"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alpha for Fabry disease: safety and effects on renal function in a home infusion setting.","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.","volume":"90","author":"Buechner","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","article-title":"Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.","volume":"31","author":"Salviati","year":"2010","journal-title":"Neurol Sci"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archneurol.2009.309","article-title":"Inherited metabolic disorders and stroke. Part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes.","volume":"67","author":"Testai","year":"2010","journal-title":"Arch Neurol"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2008.12.028","article-title":"Amelioration of white-matter lesions in a patient with Fabry disease.","volume":"279","author":"Yamadera","year":"2009","journal-title":"J Neurol Sci"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease: current treatment and new drug development.","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr Chem Genomics"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases a-galactosidase A levels in Fabry patient cell lines.","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"R48-9-20210206","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/mt.2009.220","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.","volume":"18","author":"Khanna","year":"2010","journal-title":"Mol Ther"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajhg.2009.09.016","article-title":"Use of a modified -N-acetylgalactosaminidase in the development of enzyme replacement therapy.","volume":"85","author":"Tajima","year":"2009","journal-title":"Am J Hum Genet"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1073\/pnas.051634498","article-title":"Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.","volume":"98","author":"Jung","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","article-title":"Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.","volume":"99","author":"Takahashi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-17-26","article-title":"Characterization of Fabry mice treated with recombinant adeno-associated virus 28-mediated gene transfer.","volume":"17","author":"Choi","year":"2010","journal-title":"J Biomed Sci"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2008.10.017","article-title":"Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by single systemic injection of AAV1 vector in the neonatal period.","volume":"96","author":"Ogawa","year":"2009","journal-title":"Mol Genet Metab"},{"key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"7886","DOI":"10.1073\/pnas.1002758107","article-title":"Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders.","volume":"107","author":"Meng","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32834a9433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:13:46Z","timestamp":1786047226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-201110000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32834a9433","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}